Bifidobacterium Breve A1 Supplementation Improved Cognitive Decline in Older Adults with Mild Cognitive Impairment: An Open-Label, Single-Arm Study
We previously reported the therapeutic potential of Bifidobacterium breve A1 (B. breve A1) for preventing cognitive impairment in Alzheimer’s disease model mice, which suggested that supplementation of the probiotics could be an effective therapeutic strategy for managing cognitive function in mild cognitive impairment (MCI).
Design and Settings
We conducted an open-label, single-arm study to examine the effects of 24-week supplementation of B. breve A1 on elderly with MCI in Aki Orthopedics Rehabilitation Clinic in Japan.
27 participants were screened by their Mini Mental State Examination (MMSE) scores.
Cognitive function was assessed using MMSE and Digit Symbol Substitution Test (DSST) at baseline and every 8 weeks. Mental condition and quality of life for gastrointestinal symptoms were measured using the Profile of Mood States 2nd Edition (POMS2), and the Gastrointestinal Symptom Rating Scale (GSRS).
Of the 27 participants enrolled, 19 completed the study. MMSE scores were significantly increased during the intervention by mixed model Dunnett’s test and Wilcoxon signed-rank tests (+1.7, P < 0.01). POMS2 and GSRS scores were significantly improved during intervention when analyzed by Wilcoxon signed-rank tests.
The present study showed that oral supplementation of B. breve A1 in participants with MCI improved cognitive function, thus suggesting the potential of B. breve A1 for improving cognitive function and maintaining quality of life of the elderly. Further randomized, double-blind placebo-controlled studies are worth conducting to examine the beneficial effect of B. breve A1.
Key wordsDementia Alzheimer’s disease Bifidobacterium cognitive impairment probiotics
- 4.Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med 2011; 364: 2227–34.Google Scholar
- 13.Folstein MF, Folstein SE, McHugh PR. Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98.Google Scholar
- 15.Izawa Y, Urakami K, Kojima T, Ohama E. Wechsler Adult Intelligence Scale, 3rd Edition (WAIS-III): Usefulness in the Early Detection of Alzheimer’s Disease. Yonago Acta Med 2009; 52: 11–20.Google Scholar
- 16.Kazuhito Y, Kazuhisa W. Profile of Mood States 2nd Edition Japanese Manual (in Japanese). Kaneko shobo, Japan.Google Scholar
- 20.Kempuraj D, Thangavel R, Natteru PA, Selvakumar GP, Saeed D, Zahoor H et al. Neuroinflammation Induces Neurodegeneration. J Neurol Neurosurg spine 2016; 1.Google Scholar
- 21.Portincasa P, Maggipinto A, Berardino M, Bonfrate L, Costin S, Todarello O et al. Assessing gastrointestinal symptoms and perception, quality of life, motility, and autonomic neuropathy in clinical studies. J Gastrointestin Liver Dis 2009; 18: 205–11.Google Scholar
- 23.Blum S, Schiffrin EJ. Intestinal microflora and homeostasis of the mucosal immune response: implications for probiotic bacteria? Curr Issues Intest Microbiol 2003; 4: 53–60.Google Scholar